Blood-based Biomarkers for Monitoring Antiangiogenic Therapy in Non-small Cell Lung Cancer

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2016 Aug 29

PMID 27568331

Citations 3

Authors

Analia Rodriguez Garzotto

C Vanesa Diaz-Garcia

Alba Agudo-Lopez

Elena Prieto Garcia

Santiago Ponce

Jose A Lopez-Martin

Luis Paz-Ares

Lara Iglesias

M Teresa Agullo-Ortuno

Affiliations

Soon will be listed here.

Abstract

Tumor angiogenesis pathways have been identified as important therapeutic targets in non-small cell lung cancer. However, no biomarkers have been described as predictors of response to antiangiogenic therapy in these patients. In this study, plasma levels of VEGF, bFGF, E-selectin, and S-ICAM and gene expression profiles of peripheral blood mononuclear cells from non-small cell lung cancer patients treated with chemotherapy plus bevacizumab were analyzed before and after treatment. Values were correlated with clinicopathological characteristics and treatment response. Plasma factor levels were measured using commercially available ELISA kits. The TaqMan(®) human angiogenesis array was used to investigate the effect of treatment on gene expression profiles. Kyoto Encyclopedia of Genes and Genomes and Gene Ontology enrichment analysis was performed for differentially expressed genes using WEB-based GEne SeT AnaLysis Toolkit. Our results suggest a benefit for patients with increased plasma levels of VEGF, E-selectin, and S-ICAM in the course of bevacizumab treatment. Also, we identified differentially expressed genes between paired blood samples from patients before and after treatment, and significantly perturbed pathways were predicted. These changes in gene expression and levels of plasma factors could be used to assess the effectiveness of antiangiogenic therapy, in addition to standard clinical and radiological evaluations.

Citing Articles

The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel Inhibition.

Daum S, Hagen H, Naismith E, Wolf D, Pircher A Front Cell Dev Biol. 2021; 8:610903.

PMID: 33469537 PMC: 7813779. DOI: 10.3389/fcell.2020.610903.

A glassy carbon electrode modified with TiO(200)-rGO hybrid nanosheets for aptamer based impedimetric determination of the prostate specific antigen.

Karimipour M, Heydari-Bafrooei E, Sanjari M, Johansson M, Molaei M Mikrochim Acta. 2018; 186(1):33.

PMID: 30564911 DOI: 10.1007/s00604-018-3141-7.

A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.

Pace A, Mandoj C, Antenucci A, Villani V, Sperduti I, Casini B J Neurooncol. 2018; 138(3):527-535.

PMID: 29594657 DOI: 10.1007/s11060-018-2820-x.

References

Poon R, Fan S, Wong J . Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001; 19(4):1207-25. DOI: 10.1200/JCO.2001.19.4.1207. View

Hlatky L, Hahnfeldt P, Folkman J . Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002; 94(12):883-93. DOI: 10.1093/jnci/94.12.883. View

Wang J, Duncan D, Shi Z, Zhang B . WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013; 41(Web Server issue):W77-83. PMC: 3692109. DOI: 10.1093/nar/gkt439. View

Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N . Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res. 2015; 7:133-43. PMC: 4461138. DOI: 10.2147/CMAR.S77400. View

Muturi H, Dreesen J, Nilewski E, Jastrow H, Giebel B, Ergun S . Tumor and endothelial cell-derived microvesicles carry distinct CEACAMs and influence T-cell behavior. PLoS One. 2013; 8(9):e74654. PMC: 3770572. DOI: 10.1371/journal.pone.0074654. View

Reck M, Kaiser R, Mellemgaard A, Douillard J, Orlov S, Krzakowski M . Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15(2):143-55. DOI: 10.1016/S1470-2045(13)70586-2. View

Garon E, Ciuleanu T, Arrieta O, Prabhash K, Syrigos K, Goksel T . Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384(9944):665-73. DOI: 10.1016/S0140-6736(14)60845-X. View

Weis S, Cheresh D . Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005; 437(7058):497-504. DOI: 10.1038/nature03987. View

Muller M, Singer B, Klaile E, Obrink B, Lucka L . Transmembrane CEACAM1 affects integrin-dependent signaling and regulates extracellular matrix protein-specific morphology and migration of endothelial cells. Blood. 2005; 105(10):3925-34. DOI: 10.1182/blood-2004-09-3618. View

10.

Dowlati A, Gray R, Sandler A, Schiller J, Johnson D . Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clin Cancer Res. 2008; 14(5):1407-12. DOI: 10.1158/1078-0432.CCR-07-1154. View

11.

Vasudev N, Reynolds A . Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014; 17(3):471-94. PMC: 4061466. DOI: 10.1007/s10456-014-9420-y. View

12.

Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I . Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res. 2005; 11(20):7344-53. DOI: 10.1158/1078-0432.CCR-05-1077. View

13.

Huang D, Sherman B, Lempicki R . Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2008; 37(1):1-13. PMC: 2615629. DOI: 10.1093/nar/gkn923. View

14.

Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N . Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010; 11(8):733-40. DOI: 10.1016/S1470-2045(10)70151-0. View

15.

Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N . Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer. 2006; 53(1):91-6. DOI: 10.1016/j.lungcan.2006.02.009. View

16.

Stefanini M, Wu F, Mac Gabhann F, Popel A . Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res. 2010; 70(23):9886-94. PMC: 3058319. DOI: 10.1158/0008-5472.CAN-10-1419. View

17.

Bertolini F . Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells. Cancer Metastasis Rev. 2007; 27(1):95-101. DOI: 10.1007/s10555-007-9110-y. View

18.

Zaman K, Driscoll R, Hahn D, Werffeli P, Goodman S, Bauer J . Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. Int J Cancer. 2005; 118(3):755-64. DOI: 10.1002/ijc.21408. View

19.

Smirnov D, Foulk B, Doyle G, Connelly M, Terstappen L, OHara S . Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Res. 2006; 66(6):2918-22. DOI: 10.1158/0008-5472.CAN-05-4003. View

20.

Pajares M, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I . Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol. 2012; 30(10):1129-36. PMC: 4874209. DOI: 10.1200/JCO.2011.37.4231. View